RESEARCH MONOGRAPH · KDC-MN-092

Melanotan I (Afamelanotide)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

72/100

Linear alpha-MSH analog with EMA approval for erythropoietic protoporphyria, the most legitimate melanotan compound by clinical evidence

Melanotan I (afamelanotide, Scenesse) is the linear 13-residue alpha-MSH analog developed at the University of Arizona by Hadley and Hruby in the 80s, with a Nle4-D-Phe7 modification to confer protease resistance and prolonged MC1R activation. It received EMA approval in 2014 and FDA approval in 2019 for erythropoietic protoporphyria (EPP), a rare photosensitivity disorder where increased melanization provides actual protective benefit.

What we like is that this is the only melanocortin agonist with serious approval-grade clinical evidence behind it. The EPP trials showed reproducible photosensitivity reduction with clear quality-of-life endpoints, the implant formulation (Scenesse is a subcutaneous bioabsorbable polymer implant) gives sustained MC1R activation for about 2 months per dose, and the safety profile in approved use is acceptable. The pharmacology story is clean: alpha-MSH receptor agonism at MC1R drives melanocyte tyrosinase activation and increased eumelanin production, which protects against the porphyrin-induced photoreactive damage in EPP.

What we dont like: the indication is genuinely narrow. EPP affects probably 1 in 75,000 people, and outside this indication the use of Melanotan I is essentially off-label cosmetic tanning, which has different risk-benefit math entirely. The hyperpigmentation that's therapeutic in EPP is the cosmetic effect that drove most non-medical use, and the long-term effects of chronic MC1R activation on melanoma surveillance biology are not fully characterized. The European pharmacovigilance signal on melanoma in non-EPP off-label users is something to take seriously even if the absolute risk numbers remain debated.

Sourcing for research-grade is reasonably good. The 13-residue modified peptide is straightforward Fmoc-SPPS and reputable vendors produce HPLC pure material reliably. Watch for D-Phe7 stereochemistry, since the D-isomer is essential for protease resistance and cheaper vendors sometimes have racemization issues.

For research on MC1R pharmacology, melanocortin-driven pigmentation biology, and as a positive control in melanocortin receptor work, Melanotan I is the most legitimately characterized compound in the class. The EPP approval grounds it in real clinical evidence that the other melanotans lack. Treat it as the laboratory pharmacology tool with real biology behind it.

Evidence: 78
Mechanism: 85
Reliability: 75
Safety: 65
Sourcing: 75
Value: 65
Signal: 70
Staying power: 65

Plain-language summary Intrigue 70 / 100

Melanotan I (afamelanotide), sold as Scenesse, is a linear melanocortin receptor agonist approved for erythropoietic protoporphyria (a rare light-sensitivity disorder). It produces skin tanning by activating melanin synthesis. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Alpha-MSH analog (linear heptadecapeptide)

A linear alpha-MSH analog approved as Scenesse for erythropoietic protoporphyria, characterized by sustained skin pigmentation.

Abstract

Melanotan I (Afamelanotide, Scenesse; (Nle4, D-Phe7)-alpha-MSH; CAS 75921-69-6; molecular formula C78H111N21O19; molecular weight 1646.85) is a linear heptadecapeptide analog of alpha-melanocyte stimulating hormone (alpha-MSH) developed at the University of Arizona by Mac Hadley's group in the 1980s. The compound was approved by the FDA in 2019 (and earlier in Europe) for erythropoietic protoporphyria, a rare genetic photosensitivity disorder. Mechanism is non-selective melanocortin receptor agonism (MC1, MC3, MC4, MC5); the MC1 activity drives melanin synthesis in melanocytes producing tan-like skin pigmentation. The clinical formulation is a 16 mg subcutaneous implant providing sustained release over approximately 60 days. The compound is sold as a research chemical/peptide for sunless tanning applications, though regulatory authorities have issued warnings against this use. Pharmacokinetics: subcutaneous administration; the implant formulation provides 30 to 60 days of activity per implant.

Mechanism of action

Non-selective melanocortin receptor agonist (MC1-MC5). MC1 activity drives skin pigmentation.

Reported research dose ranges

16 mg implant providing roughly 60 days of activity (reported research dose range in the literature).

References

Langendonk JG, et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med 2015.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-092

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Melanotan I (Afamelanotide)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs